Kaya
Holdings, Inc.'s V.P. Bryan Arnold Among First Ten (10) State
Licensed Psilocybin Facilitators in U.S.A.
KAYS'
Fifth Dimension Therapeutics Plans to Open "The Sacred
Mushroom™"
Psilocybin Centers in Oregon, Marking Entry into the Global
Psychedelics Market, which is Forecast to Exceed $8 Billion by
2029.
FT.
LAUDERDALE, FL -- May 24, 2023 -- InvestorsHub NewsWire
-- Kaya
Holdings, Inc., ("KAYS" or the "Company") (OTCQB:KAYS),
congratulates
Bryan Arnold, a dedicated 9-year Kaya employee and Vice President
with KAYS subsidiary Fifth Dimension Therapeutics, Inc. ("FDT"),
for being among the first graduates of the Changa Institute and
among the first ten (10) state Licensed Psilocybin Facilitators in
the United States. The Company is proud of Bryan and look forward
to his contribution as we seek to develop and launch "The Sacred
Mushroom™" Psilocybin Centers in accordance with Oregon State
law.
KAYS' Fifth Dimension Subsidiary Vice President Bryan
Arnold
is one of the first people to be licensed to facilitate psilocybin
experiences
in the United States outside of clinical trials in over 50
years.
As reported
by Bloomberg in July of 2022, "the
rise in stress levels and the growing rate of chronic diseases
throughout the world is predicted to propel the global psychedelic
medicines market expansion… the value of the Global Psychedelic
Therapeutic Market is expected to grow from US$ 3.61 billion in
2021 to US$8.31 billion by 2028, with a CAGR of 13.2%."
In January
2023 KAYS announced the launch of its FDT subsidiary to provide
psychedelic "mind care" treatments to veterans suffering from PTSD,
addicts seeking to break addiction, individuals with eating
disorders, and people with treatment resistant depression and other
mental health disorders. We are pleased to report this milestone
and will update shareholders as we move forward with our plans to
open our first Psilocybin Service Center to service the growing
Psychedelics Market.
"An
uncomfortable fact is that approximately every 40 seconds someone
around the world commits suicide," stated W. David Jones, KAYS
Senior Advisor for Business Development and Financial Operations.
"Picture a football stadium filled with 65,000 fans. That's how
many people die from suicide every month, and this doesn't even
consider the toll on the millions of family members and friends who
are left behind, or the more than 100 million people struggling
through their lives because of ineffectual mental health
treatments" continued Jones. "We are moving to establish a unique
facility dedicated to helping people leverage the power of
psychedelics for richer, fuller, and more joyful living, pursuant
to Oregon Health Authority requirements and statutes."
"My
experiences at the Changa Institute transformed my understanding of
psychedelics", says Bryan Arnold, Vice President of the Company's
Psychedelic unit. "I have gained a tremendous respect for the power
of psychedelics and am excited by the potential it has to help
people with certain mental health conditions. Being part of the
KAYS team introducing psychedelics to the people of Oregon is both
a responsibility and an honor, and The Sacred Mushroom™ will
reflect our deep respect for psychedelics and the potential they
hold to help or heal," Arnold continues.
Changa Institute Graduates First Licensed US Psychedelic
Facilitators:
https://psychedelichealth.co.uk/2023/04/03/changa-institute-first-licensed-us-psychedelic-facilitators/
Updated Information about Kaya Holdings,
Inc.
http://icont.ac/4QBdX
Kaya
Holdings, Inc. (OTCQB:KAYS)
is a Mind Care Company with longstanding operations as a
touch-the-plant, vertically integrated legal cannabis business. The
Company is evolving into a full mind care enterprise with the
planned introduction of psilocybin and ketamine treatments, as
permitted by State Law, as we seek to expand our medical cannabis
business overseas. KAYS is a fully reporting, US-based publicly
traded company, listed for trading on the OTCQB Tier of the
over-the-counter market under the symbol KAYS.
Shareholder Hotline:
For more information, please call 954-480-1270 or email
info@kayaholdings.com
to speak with our new Corporate Communications Manager
regarding your
investment in KAYS.
KAYS SHAREHOLDERS AND OTHER INTERESTED PARTIES - PLEASE UPDATE YOUR
CONTACT INFORMATION
We
routinely receive calls and emails from shareholders asking us
questions about KAYS, so we are asking all KAYS shareholders to
email us and confirm their contact info. Please email
info@kayaholdings.com with "KAYS shareholder update" in the subject
line and include your name, address, phone number and number of
shares you own so that we may make sure you receive all updates and
can respond to any shareholder inquiries.
Summary of Operations
KAYS
corporate structure includes the following four majority-owned
subsidiaries, each responding to various demands and opportunities
in the cannabis or psychedelic industry:
Fifth Dimension Therapeutics, Inc. , serves
as the Company's operating branch to the psychedelic treatment
sector, including operation of mushroom cultivation facilities and
in-facility treatment centers.
Marijuana Holdings Americas, Inc.
owns the Kaya Shack™ brand of licensed medical and recreational
marijuana stores (www.kayashack.com)
and the Kaya Farms™ brand of cannabis production and processing
operations that operate in the United States.
Kaya Brands International, Inc., serves
as the vehicle for the Company's non-U.S. operations including
cultivation activities in Greece and Israel.
Kaya Brands USA, Inc. owns a
wide range of proprietary brands of cannabis extracts, oils,
pre-rolls, topicals, edibles and beverages, cannaceuticals and
related accessories.
Important Disclosure
KAYS is
planning execution of its stated business objectives in accordance
with current understanding of state and local laws and federal
enforcement policies and priorities as it relates to cannabis and
psychedelics. Potential investors and shareholders are cautioned
that KAYS and subsidiaries including FTD will obtain advice of
counsel prior to actualizing any portion of their business plan
(including but not limited to license applications for the
cultivation, distribution or sale of marijuana and psychedelic
products, engaging in said activities or acquiring existing
production/sales operations). Advice of counsel with regard to
specific activities of KAYS, federal, state or local legal action
or changes in federal government policy and/or state and local laws
may adversely affect business operations and shareholder value.
Success of our business plan including the launch of "The Sacred
Mushroom™" Psilocybin Facilitation Centers depends on many factors
including receipt of requisite funding to build out and staff the
Centers.
Forward-Looking Statements
This press
release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, acceptance of the Company's current and future products
and services in the marketplace, the ability of the Company to
develop effective new products and receive regulatory approvals of
such products, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. By making
these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release.
SOURCE: Kaya
Holdings, Inc.